Astellas is at an inflection point in our evolution, facing opportunities presented by our growing pipeline, but amidst a rapidly changing environment that is transforming the ways every segment...

Improved score marks continuing effort in growing inclusive culture to support people with disabilities For the second year in a row, Astellas has been included in the Disability Equality Index as...

Astellas, through its Mitobridge affiliate, has dosed the first patient in its pivotal Phase 2/3 clinical trial for ASP0367*, an oral investigational drug that may improve exercise intolerance and...

Astellas Pharma Inc. announced changes in its Global Commercial Leadership Team reporting to Chief Commercial Officer Yukio Matsui aligned with the focuses for the new Corporate Strategic Plan 2021 (CSP2021).

To further our mission to meet patients’ unmet medical needs through innovative pharmaceutical products, we recently announced several strategic executive promotions in the Quality Assurance...

As part of our ranking among Working Mother Magazine’s Top 10 companies and among the top 30 for working dads, we selected Dominique Talbert, director Scientific Publications, Medical &...

An Interview with Astellas US President Percival Barretto-Ko recently shared his day-to-day experience in his role as well as some of the key focus areas that are critical to the future of...

By Yoshitsugu Shitaka, President, Astellas Institute for Regenerative Medicine Astellas strives to be on the forefront of healthcare change and our work in regenerative medicine is a clear example...

Nov 29, 2016 When Astellas’ President of Global Development, Dr. Bernie Zeiher, was in medical school, his mother succumbed to pancreatic cancer – a disease that afflicts tens of thousands of...

By Bernhardt G. Zeiher, MD, FACP, FCCP, Chief Medical Officer The biopharmaceutical R&D enterprise is in the midst of a period of significant change and challenge. Over the last decade,...